Ignite Creation Date:
2024-05-06 @ 9:48 AM
Last Modification Date:
2024-10-26 @ 12:19 PM
Study NCT ID:
NCT03070093
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2021-04-20
First Post:
2017-02-28
Brief Title:
Expanded Access Study of Gilteritinib ASP2215 in Patients With FMS-like Tyrosine Kinase 3 FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia AML or FLT3-Mutated AML in Complete Remission CR With Minimal Residual Disease MRD
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc